A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
A pharmaceutical company needed to understand the efficacy and tolerability of a pain relief drug in post-operative and non-surgical patients with moderate to severe pain. The sponsor needed to capture data from both hospitalized and out-patient participants.
VaxArt needed solutions for evaluating the safety and immunogenicity of its orally administered norovirus vaccine. Of particular importance was incorporating a way to quickly detect severe reactogenicity symptoms during the first week following vaccine administration.
A government agency is aiming to identify digital biomarkers of depressive and anxious feelings. The agency needed to capture both objective and subjective data for analysis.